United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics (Nasdaq: UTHR) announced it will feature clinical data and sponsor events at the CHEST 2025 Annual Meeting in Chicago, October 19–22, 2025.

Two oral rapid‑fire presentations on Oct 21, 2025: 10:44–10:48 AM CDT — interim PHINDER echocardiographic analysis; 2:03–2:07 PM CDT — impact of inhaled treprostinil initiation timing on hospitalizations in PH‑ILD.

Sponsored events include a fellows breakfast (Oct 18), Women in Chest Medicine luncheon (Oct 20), APP networking event (Oct 20), and a PHinding PH symposium (Oct 20, 6:00–9:00 PM CDT).

United Therapeutics (Nasdaq: UTHR) has announced a webcast to present data from their successful TETON-2 pivotal study of nebulized Tyvaso® for treating idiopathic pulmonary fibrosis (IPF). The presentation will take place on September 28, 2025, at 12:30 p.m. ET.

Dr. Steven D. Nathan, Chair of the TETON Steering Committee, will lead the presentation of data previously shown at the European Respiratory Society Congress. The study successfully met its primary endpoint, demonstrating improvement in absolute forced vital capacity (FVC) compared to placebo, with significant improvements also observed in most secondary endpoints.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CEO Martine Rothblatt will participate in a fireside chat at the Bernstein 2nd Annual Healthcare Forum in New York. The presentation is scheduled for September 23, 2025, from 1:10 p.m. to 1:50 p.m. EST.

Investors can access the session through a live webcast on the company's website, with a recorded version available for 90 days after the event. As a unique pharmaceutical company structured as a public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) announced its upcoming presentations at the European Respiratory Society (ERS) Congress in Amsterdam from September 27 - October 1, 2025. The company will showcase key clinical data including the phase 3 TETON-2 study results of inhaled treprostinil for idiopathic pulmonary fibrosis.

The presentations will feature multiple research findings, including interim data from the ADVANCE EXTENSION study evaluating ralinepag for pulmonary arterial hypertension, and discoveries from the PHINDER study focused on improving pulmonary hypertension detection in patients with interstitial lung disease. The congress will include oral presentations, poster sessions, and mini-symposia covering various aspects of United Therapeutics' commercial and development portfolio.

United Therapeutics (NASDAQ:UTHR) announced that its TETON-2 pivotal study of Tyvaso® (treprostinil) Inhalation Solution for treating idiopathic pulmonary fibrosis (IPF) has met its primary endpoint. The study demonstrated a significant improvement in forced vital capacity (FVC) of 95.6 mL compared to placebo at 52 weeks (p<0.0001).

The treatment showed benefits across all subgroups and achieved statistical significance in key secondary endpoints, including time to first clinical worsening event, percent predicted FVC, quality of life measures, and lung diffusion capacity. The safety profile was consistent with previous studies, with no new safety concerns identified.

United Therapeutics plans to use data from both TETON-2 and the ongoing TETON-1 study to support a supplemental New Drug Application for IPF indication. TETON-1 results are expected in the first half of 2026.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CFO James Edgemond will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The presentation is scheduled for September 8, 2025, from 3:20 PM to 3:55 PM EST.

The session will be accessible through a live webcast on the company's investor relations website, with a recorded version available for 90 days after the event. As a unique publicly-traded biotech company structured as a public benefit corporation (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) has announced a significant $1 billion Accelerated Share Repurchase (ASR) program, structured through two $500 million agreements with Citibank - one collared and one uncollared. The company will make an upfront payment of $1 billion on August 4, 2025, receiving approximately 75% of shares under the uncollared agreement and 50% under the collared agreement initially.

The final settlement for the uncollared ASR is expected in Q4 2025, while the collared ASR will settle in Q1 2026. The repurchase program, authorized on July 30, 2025, demonstrates the company's confidence in its intrinsic value and upcoming catalysts. As of July 30, 2025, UTHR had approximately 45.2 million shares outstanding.

United Therapeutics (NASDAQ:UTHR) reported strong Q2 2025 financial results with record total revenue of $798.6 million, up 12% year-over-year, marking 12 consecutive quarters of double-digit growth. The company's Board authorized a $1 billion share repurchase program through March 2026.

Key highlights include Tyvaso DPI's record revenue of $315.2 million (22% growth), strong performance from Nebulized Tyvaso, Orenitram, and Unituxin. Net income reached $309.5 million ($6.41 per diluted share). The company expects continued double-digit revenue growth, supported by its commercial portfolio and late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.

Important upcoming catalysts include the TETON 2 study results in September 2025 for idiopathic pulmonary fibrosis and ADVANCE OUTCOMES study data in H1 2026 for pulmonary arterial hypertension.

United Therapeutics (NASDAQ: UTHR) has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025, before market open. The company will release detailed quarterly results via press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.

The webcast will be available through the company's investor relations website at ir.unither.com/events-and-presentations, with a rebroadcast accessible for one year afterward. United Therapeutics operates as a public benefit corporation (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.